CABA
Cabaletta Bio, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 14 ▲ Cabaletta Bio presented new clinical data at ASGCT 2026 showing that…
- May 14 ▼ Cabaletta Bio reported Q1 2026 net loss of $43.5M (EPS -$0.39, beati…
- Jun 3 ▲ Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel…
- Nov 8 FDA: Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Dat…
- Nov 8 ▲ Cabaletta Bio presented new Phase 1/2 data at ACR Convergence 2026 s…
- Nov 9 ▲ Cabaletta Bio presented new Phase 1/2 clinical data for rese-cel at…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 36 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
13 of 16 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.317 → −$0.283 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −2.3% to 38.37M shares. 8.2 days to cover, ≈17.8% of shares.
- TrendDOWNTREND
41% below its 50-day average. New closing low $1.11 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $27.6M |
| MORGAN STANLEY | ADD | $4.5M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $4.4M |
| Qube Research & Technologies Ltd | ADD | $4.0M |
| FMR LLC | DOUBLED | $2.9M |
| Nuveen, LLC | ADD | $2.0M |
| TD ASSET MANAGEMENT INC | ADD | $1.3M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | $740.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
16 analystsPrice is below the lowest target. Median implies +1116%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Citigroup MAINTAIN | Buy |
| Sep 1, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 14, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Brun Scott C. Director Jun 9, 2026 | AWARD | 22,000 sh |
Bollard Catherine Director Jun 9, 2026 | AWARD | 22,000 sh |
HENRIQUES RICHARD C JR Director Jun 9, 2026 | AWARD | 22,000 sh |
Simon Mark Director Jun 9, 2026 | AWARD | 22,000 sh |
Tomasello Shawn Director Jun 9, 2026 | AWARD | 22,000 sh |
Chang David J. Chief Medical Officer Mar 2, 2026 | AWARD | 225,000 sh |
Gerard Michael General Counsel Mar 2, 2026 | AWARD | 175,000 sh |
Binder Gwendolyn President, Science & Tech. Mar 2, 2026 | AWARD | 225,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.28 | -$0.35–-$0.23 | +9.1% | $0.00 |
| Next Q | -$0.28 | -$0.36–-$0.24 | +5.1% | $0.00 |
| Current FY | -$1.29 | -$1.41–-$1.18 | +5.1% | $0.00 |
| Next FY | -$1.13 | -$1.54–-$0.87 | +5.3% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
27 filings · 2 press releases · 6 bullish · 3 bearish · 18 neutral- NEUTRAL SC 13G/ANov 16, 2026
Cormorant Asset Management filed an amended Schedule 13G for Cabaletta Bio, reporting beneficial ownership of 4,500,000 shares (2.65% of common stock) as of September 30, 2026. No prior Cormorant 13G for CABA is in the provided context for comparison, so the direction of change is unknown.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Bain Capital Life Sciences Opportunities III, LP filed an amended Schedule 13G for Cabaletta Bio, reporting beneficial ownership of 21,209,188 shares (9.57% of common stock) as of September 30, 2026, including a pre-funded warrant for 6,000,000 shares. This is a routine passive stake update by a…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 12, 2026
Norges Bank filed an amended Schedule 13G for Cabaletta Bio, reporting beneficial ownership of…
Monitor for any future Norges Bank 13G amendments to track stake direction. A passive sovereign fund holding below 5% has no material impact on trading or governance.
- NEUTRAL INST-CLUSTERNov 9, 2026
Nine institutional investors increased their CABA positions in Q3 2026, with three doubling their…
The cluster is modest in dollar terms relative to CABA's $214M market cap. The absence of insider buying weakens conviction. Monitor upcoming clinical catalysts (RESET-Myositis topline in 2H27) for…
All CABA filing & press-release reports (29)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 12, 2026
- INST-CLUSTER reportNov 9, 2026
- 8-K reportNov 9, 2026
- PRESS-RELEASE reportNov 8, 2026
- SC 13G/A reportNov 6, 2026
- SC 13G/A reportNov 6, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 5, 2026
- SC 13G/A reportOct 30, 2026
- SC 13G/A reportOct 27, 2026
- 8-K reportSep 14, 2026
- INST-CLUSTER reportAug 15, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 3, 2026
- DEFA14A reportJun 1, 2026
- 8-K reportMay 14, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- 8-K reportMay 4, 2026
- 424B5 reportMay 4, 2026
- 8-K reportMay 4, 2026
- DEFA14A reportApr 28, 2026
- 8-K reportApr 20, 2026
- PRESS-RELEASE reportMar 23, 2026
- INST-CLUSTER reportFeb 28, 2026